Several lines of evidence suggest a meaningful association between obsessive-compulsive disorder and Tourette syndrome, including comorbidity, phenomenologic overlap, evidence from family and genetic studies, and the possible role of basal ganglia circuitry in both conditions. Obsessive-compulsive behaviors occur frequently in patients who have Tourette syndrome and tend to have a later onset than tics. Despite commonalities, the approaches to treating tics and obsessive-compulsive symptoms are actually quite distinct. A specialized form of cognitive behavior therapy and pharmacotherapy with a potent serotonin reuptake inhibitor are the two established first-line therapies for obsessive-compulsive disorder. An adequate trial of a serotonin reuptake inhibitor is 10 to 12 weeks in duration at doses near the upper end of the recommended range for age and weight. Cases of obsessive-compulsive disorder that do not sufficiently improve with serotonin reuptake inhibitors might benefit from adjunctive low-dose antipsychotic (eg, risperidone) medication whether or not tics are present. Warnings about an increased risk of suicidality among children and adolescents taking antidepressants for pediatric depression extend to those taking the medications for obsessive-compulsive disorder, but the risk-to-benefit ratio is more favorable in this latter population because several serotonin reuptake inhibitors have been shown to be efficacious in obsessive-compulsive disorder. (J Child Neurol 2006;21:704— 714; DOI 10.2310/7010.2006.00169).
Get full access to this article
View all access options for this article.
References
1.
Leckman JF, Pauls DL, Cohen DJ: Tic disorders, in Bloom FE, Kupfer DJ, (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, 1665—1674.
2.
Bloch MH, Peterson BS, Scahill L., et al: Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch Pediatr Adolesc Med2006;160: 65—69.
3.
Peterson BS, Pine DS, Cohen P., Brook JS: Prospective, longitudinal study of tic, obsessive-compulsive, and attention-deficit/ hyperactivity disorders in an epidemiological sample. J Am Acad Child Adolesc Psychiatry2001;40:685—695.
4.
Leckman JF, Chittenden EH: Gilles de La Tourette's syndrome and some forms of obsessive-compulsive disorder may share a common genetic diathesis. Encephale1990;16(Spec No):321—323.
5.
Santangelo SL , Pauls DL, Goldstein JM, et al: Tourette's syndrome: What are the influences of gender and comorbid obsessive-compulsive disorder?J Am Acad Child Adolesc Psychiatry1994;33:795—804.
6.
Scahill L., Kano Y., King RA, et al: Influence of age and tic disorders on obsessive-compulsive disorder in a pediatric sample. J Child Adolesc Psychopharmacol2003;13(Suppl 1):S7—S17.
7.
Holzer JC, Goodman WK, McDougle CJ, et al: Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry1994; 164:469—473.
8.
Horwath E., Weissman MM: The epidemiology and cross-national presentation of obsessive-compulsive disorder . Psychiatr Clin North Am2000;23:493—507.
9.
Goodman WK, Price LH, Rasmussen SA, et al: The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry1989;46:1006—1011.
10.
Goodman WK, Price LH, Rasmussen SA, et al: The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry1989;46:1012—1016.
11.
Pauls DL, Leckman JF: The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. N Engl J Med1986;315:993—997.
Geller D., Biederman J., Jones J., et al: Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature. J Am Acad Child Adolesc Psychiatry1998;37:420—427.
14.
Leonard HL, Lenane MC, Swedo SE, et al: Tics and Tourette's disorder: A 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry1992;149:1244—1251.
15.
Grados MA, Riddle MA, Samuels JF, et al: The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: The Hopkins OCD family study. Biol Psychiatry2001; 50:559—565.
16.
Nestadt G., Samuels J., Riddle M., et al: A family study of obsessive-compulsive disorder. Arch Gen Psychiatry2000;57:358—363.
17.
Murphy TK, Sajid M., Soto O., et al: Detecting pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in children with obsessive-compulsive disorder and tics . Biol Psychiatry2004;55:61—68.
18.
Mell LK, Davis RL, Owens D.: Association between streptococcal infection and obsessive-compulsive disorder, Tourette's syndrome, and tic disorder. Pediatrics2005;116:56—60.
19.
Swedo SE, Leonard HL, Garvey M., et al: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: Clinical description of the first 50 cases. Am J Psychiatry1998;155:264—271.
20.
Wagner KD, Cook EH, Chung H., Messig M.: Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol2003;13(Suppl 1): S53—S60.
21.
Reddy YC, Srinath S., Prakash HM, et al: A follow-up study of juvenile obsessive-compulsive disorder from India. Acta Psychiatr Scand2003;107:457—464.
22.
Stewart SE, Geller DA, Jenike M., et al: Long-term outcome of pediatric obsessive-compulsive disorder: A meta-analysis and qualitative review of the literature. Acta Psychiatr Scand2004; 110:4—13.
23.
Eisen JL, Goodman WK, Keller MB, et al: Patterns of remission and relapse in obsessive-compulsive disorder: A 2-year prospective study. J Clin Psychiatry1999;60:346——351; quiz 352.
Leonard HL, Swedo SE, Lenane MC, et al: A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents. Arch Gen Psychiatry1993;50:429—439.
26.
Flament MF, Koby E., Rapaport JL, et al: Childhood obsessive-compulsive disorder: A prospective follow-up study. J Child Psychol Psychiatry1990;31:363—380.
27.
Hollingsworth C., Tanguay P., Grossman L., Pabst P.: Long-term outcome of obsessive-compulsive disorder in childhood. J Am Acad Child Adolesc Psychiatry1980;19:134—144.
28.
Berg CZ, Rapoport JL, Whitaker A., et al: Childhood obsessive compulsive disorder: A two-year prospective follow-up of a community sample. J Am Acad Child Adolesc Psychiatry1989; 28:528—533.
29.
Thomsen PH, Mikkelsen HU: Course of obsessive-compulsive disorder in children and adolescents: A prospective follow-up study of 23 Danish cases. J Am Acad Child Adolesc Psychiatry1995;34:1432—1440.
30.
Evans DW, Leckman JF, Carter A., et al: Ritual habit, and perfectionism, The prevalence and development of compulsive-like behavior in normal young children, Child Dev1997;68:58—68.
31.
Geller DA, Biederman J., Jones J., et al: Obsessive-compulsive disorder in children and adolescents: A review. Harv Rev Psychiatry1998;5:260—273.
32.
Storch EA, Murphy TK, Geffken GR, et al: Psychometric evaluation of the Children's Yale-Brown Obsessive-Compulsive Scale. Psychiatry Res2004;129:91—98.
33.
Scahill L., Riddle MA, McSwiggin-Hardin M., et al: Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry1997;36:844—852.
34.
Pediatric OcdTreatment Study (POTS) Team: Cognitive-behavior therapy sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: The Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA2004;292:1969—1976.
35.
Abramowitz JS, Whiteside SP, Deacon BJ: The effectiveness of treatment for pediatric obsessive-compulsive disorder: A meta-analysis. Behav Ther2005;36:55—63.
36.
Barrett P., Farrell L., Dadds M., Boulter N.: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: Long-term follow-up and predictors of outcome. J Am Acad Child Adolesc Psychiatry2005;44:1005—1014.
37.
Saxena S., Brody AL, Maidment KM, et al: Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder . Neuropsychopharmacology1999;21:683—693.
38.
Brody AL, Saxena S., Schwartz JM, et al: FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive compulsive disorder. Psychiatry Res1998;84:1—6.
39.
Geffken GR, Storch EA, Gelfand KM, et al: Cognitive-behavioral therapy for obsessive-compulsive disorder: Review of treatment techniques. J Psychosoc Nurs Ment Health Serv2004;42:44—51.
40.
Huppert JD, Franklin ME: Cognitive behavioral therapy for obsessive-compulsive disorder: An update . Curr Psychiatry Rep2005;7:268—273.
41.
Franklin ME, Foa EB: Cognitive Behavioral Treatments for Obsessive Compulsive Disorder. A Guide to Treatments That Work. 2nd ed. New York, Oxford University Press, 2002.
42.
March JS, Franklin M., Nelson A., Foa E.: Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder . J Clin Child Psychol2001;30:8—18.
43.
Barrett P., Healy-Farrell L., March JS: Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: A controlled trial. J Am Acad Child Adolesc Psychiatry2004;43:46—62.
44.
Foa EB, Liebowitz MR, Kozak MJ, et al: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry2005; 162:151-161.
45.
Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. American Association of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry1998;37(10 Suppl):27S—45S.
46.
March JS, Biederman J., Wolkow R., et al: Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial [published erratum appears in JAMA 2000;283:1293]. JAMA1998;280:1752—1756.
47.
Geller DA, Wagner KD, Emslie G., et al: Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: A randomized, multicenter, double-blind, placebo-controlled trial . J Am Acad Child Adolesc Psychiatry2004;43:1387—1396.
48.
Riddle MA, Scahill L., King RA, et al: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry1992;31:1062—1069.
49.
Leonard HL, Lenane MC, Swedo SE, et al: A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry1991; 48:821—827.
50.
Geller DA, Hoog SL, Heiligenstein JH, et al: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry2001;40:773—779.
51.
DeVeaugh-Geiss J., Moroz G., Biederman J., et al: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—A multicenter trial. J Am Acad Child Adolesc Psychiatry1992;31:45—49.
52.
Goodman WK, McDougle CJ, Price LH: The role of serotonin and dopamine in the pathophysiology of obsessive compulsive disorder. Int Clin Psychopharmacol1992;7(Suppl 1):35—38.
53.
Geller DA, Biederman J., Stewart SE, et al: Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry2003;160:1919—1928.
Pigott TA, Seay S.: Pharmacotherapy of obsessive-compulsive disorder: Overview and treatment-refractory strategies, in Goodman WK, Rudorfer MV, Maser JD (eds): Obsessive-Compulsive Disorder: Contemporary Issues in Treatment . Mahwah, NJ, Lawrence Erlbaum Associates , 2000, 277—302.
56.
McDougle CJ , Goodman WK, Leckman JF, et al: The efficacy of fluvoxamine in obsessive-compulsive disorder: Effects of comorbid chronic tic disorder. J Clin Psychopharmacol1993;13:354— 358.
57.
Shapira NA, Ward HE, Mandoki M., et al: A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry2004;55:553—555.
58.
Geller DA, Biederman J., Griffin S., et al: Comorbidity of juvenile obsessive-compulsive disorder with disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry1996;35:1637—1646.
59.
Geller DA, Biederman J., Stewart SE, et al: Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: Is the use of exclusion criteria empirically supported in randomized clinical trials?J Child Adolesc Psychopharmacol2003;13(Suppl 1):S19—S29.
60.
Findling RL : Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children adolescents, and adults, A case series. J Child Adolesc Psychopharmacol1996;6: 165—175.
61.
Saxena S., Maidment KM, Vapnik T., et al: Obsessive-compulsive hoarding: Symptom severity and response to multimodal treatment. J Clin Psychiatry2002;63:21—27.
62.
Pittenger C. , Krystal JH, Coric V.: Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx2006;3:69—81.
63.
Ninan PT, Koran LM, Kiev A., et al: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. J Clin Psychiatry2006; 67:15—22.
64.
Byerly MJ, Goodman WK, Christensen R.: High doses of sertraline for treatment-resistant obsessive-compulsive disorder . Am J Psychiatry1996;153:1232—1233.
65.
Thomsen PH: Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases: A case-series. Ann Clin Psychiatry2004;16:201—207.
66.
Murphy TK, Bengtson MA, Soto O., et al: Case series on the use of aripiprazole for Tourette syndrome . Int J Neuropsychopharmacol2005;8:489—490.
67.
Connor KM, Payne VM, Gadde KM, et al: The use of aripiprazole in obsessive-compulsive disorder: Preliminary observations in 8 patients. J Clin Psychiatry2005;66:49—51.
68.
Riddle MA, Leckman JF, Hardin MT, et al: Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome. Am J Psychiatry1988; 145:1173-1174.
69.
Delgado PL, Goodman WK, Price LH, et al: Fluvoxamine/ pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry1990; 157:762-765.
70.
McDougle CJ , Goodman WK, Leckman JF, et al: Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry1994;51:302—308.
71.
McDougle CJ , Epperson CN, Pelton GH, et al: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry2000;57:794—801.
72.
Hollander E. , Baldini Rossi N, Sood E., Pallanti S.: Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study. Int J Neuropsychopharmacol2003;6:397—401.
73.
Erzegovesi S., Guglielmo E., Siliprandi F., Bellodi L.: Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: A double-blind, placebo-controlled study. Eur Neuropsychopharmacol2005;15:69—74.
74.
Denys D., de Geus F., van Megen HJ, Westenberg HG: A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry2004;65:1040— 1048.
75.
Bystritsky A., Ackerman DL, Rosen RM, et al: Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial. J Clin Psychiatry2004;65:565—568.
76.
Carey PD, Vythilingum B., Seedat S., et al: Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: A double-blind, randomised, placebo-controlled study [ISRCTN83050762] . BMC Psychiatry2005;5:5.
77.
March JS, Frances A, Kahn DA, Carpenter D, eds. The Expert Consensus Guideline Series: Treatment of obsessive-compulsive disorder. J Clin Psychiatry1997;58(Suppl 4):2—72.
78.
Tolin DF, Maltby N., Diefenbach GJ, et al: Cognitive-behavior therapy for medication nonresponders with obsessive-compulsive disorder: A wait-list-controlled open trial. J Clin Psychiatry2004;65:922—931.
79.
Simpson HB, Gorfinkle KS, Liebowitz MR: Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: An open trial. J Clin Psychiatry1999;60:584—590.
80.
Kampman M., Keijsers GP, Hoogduin CA, Verbraak MJ: Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. Acta Psychiatr Scand2002;106:314—319.
81.
Franklin ME , Kozak MJ, Cashman LA, et al: Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: An open clinical trial. J Am Acad Child Adolesc Psychiatry1998;37:412— 419.
82.
Goodman WK, Murphy TK, Lazoritz M.: Risk of suicidality during antidepressant treatment of children and adolescents . Primary Psychiatry2006;13(1):43—50.
83.
Hammad TA, Laughren T., Racoosin J.: Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry2006;63:332—339.
84.
Leonard HL, Swedo SE, Rapoport JL, et al: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison . Arch Gen Psychiatry1989;46:1088—1092.
85.
Jermain DM, Crismon ML: Pharmacotherapy of obsessive-compulsive disorder. Pharmacotherapy1990;10:175—198.
86.
Tonks A.: Withdrawal from paroxetine can be severe, warns FDA. BMJ2002;324:260.
